Search

Your search keyword '"Fonteyne A"' showing total 435 results

Search Constraints

Start Over You searched for: Author "Fonteyne A" Remove constraint Author: "Fonteyne A" Publisher elsevier bv Remove constraint Publisher: elsevier bv
435 results on '"Fonteyne A"'

Search Results

1. Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort

2. PEACE V–Salvage Treatment of oligorecurrent nodal prostate cancer metastases (STORM): 24-months toxicity results of a randomized phase II trial

3. Incidence and radiotherapy treatment patterns of complicated bone metastases

5. ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy

7. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer

8. Transcriptomic Heterogeneity of Metastatic Disease Timing within Metastatic Castration-Sensitive Prostate Cancer

9. PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial

16. Experiences of Men With Prostate Cancer Participating in a Clinical Pathway With a Supervised Group-based Exercise Program to Combat Androgen Deprivation-Induced Side Effects: A Qualitative Focus Group Study

17. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.

21. ESTRO ACROP GUIDELINE on Prostate Bed Delineation for Postoperative Radiotherapy in Prostate Cancer

23. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

24. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer

25. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty

27. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer

28. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer

29. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty

30. Pig models for Duchenne muscular dystrophy – from disease mechanisms to validation of new diagnostic and therapeutic concepts

31. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

32. Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial

36. Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study

37. WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer

38. Evaluation of aggregate stability methods for soil health

39. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial

40. Role of WNT Pathway Mutations within Oligometastatic Castration-Sensitive Prostate Cancer

43. Long-Term Outcomes and Genetic Predictors of Response to Metastasis Directed Therapy vs. Observation in Oligometastatic Castration-Sensitive Prostate Cancer: A Pooled Analysis of the STOMP and ORIOLE Trials

44. A Tailored Radiation Therapy Strategy for Older Patients With Localized Bladder Cancer Not Eligible for Curative Treatment

45. 1381P A transcriptomic signature of AR activity prognosticates development of castration-resistance following metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer

46. An evaluation of carbon indicators of soil health in long-term agricultural experiments

47. Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial

Catalog

Books, media, physical & digital resources